Opendata, web and dolomites

Lymphit

LYMPHIT: an innovative easy-to-use and cost-efficient diagnostic microneedle patch for the early detection of Lymphedema

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Lymphit project word cloud

Explore the words cloud of the Lymphit project. It provides you a very rough idea of what is the project "Lymphit" about.

complications    prescribe    status    accumulation    secondary    fda    profile    minimally    agent    care    microneedles    acute    later    company    diagnostic    earliest    fold    generating    64    extremely    tool    boost    clinical    worsening    polymeric    fifth    approved    oncologic    first    sme    treatments    diagnosis    conservative    debilitation    safety    market    additional    commercialized    50    function    stage    life    empowering    social    disrupting    progressive    dicronis    quantitatively    detect    outlined    revenues    clinicians    complete    productivity    practitioners    398m    disease    decreasing    25    painless    optically    contain    reduce    decay    swelling    limb    chronic    icg    inadequate    optimization    instrument    healthcare    manner    markets    fluorescence    lymphit    ftes    serious    patient    lymphedema    lymphatic    invasive    patients    global    patches    fluorescent    completion    roi    medical    physical    tracking    scalable    dissolving    occurring    psychological    quality    validation    worldwide    fluids    selectively    detection   

Project "Lymphit" data sheet

The following table provides information about the project.

Coordinator
DICRONIS SAGL 

Organization address
address: VIA CAMPAGNA 57
city: MONTEGGIO
postcode: 6998
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.dicronis.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DICRONIS SAGL CH (MONTEGGIO) coordinator 50˙000.00

Map

 Project objective

Lymphedema is a chronic condition, outlined by a progressive accumulation of fluids in a limb, leading to great physical and psychological debilitation of the affected patient and often occurring secondary to oncologic treatments. There is not early diagnosis for lymphedema. Current diagnostic methods are highly inadequate and detect the disease only at an advanced stage, leading to serious complications, greatly decreasing quality-of-life of the patients while increasing healthcare costs. In response to this challenge, Dicronis has developed a diagnostic tool (LYMPHIT) based on a painless and minimally-invasive delivery of ICG, an FDA approved fluorescent agent, with an extremely high safety profile, integrated into polymeric dissolving microneedles patches which allows determining the status of the lymphatic system by optically measurement of the fluorescence decay. LYMPHIT enables patients and clinicians the earliest possible detection of lymphedema, by quantitatively tracking the function of the lymphatic system in a painless, easy-to-use and highly-scalable manner. LYMPHIT will be disrupting in the market by empowering medical practitioners to timely and selectively prescribe conservative treatments, which can contain or avoid a worsening of the swelling in the affected limb. Therefore, LYMPHIT will reduce lymphedema treatments costs up to 50% and reduce 10-fold the social costs associated to productivity loss, both of them associated with late stage lymphedema. Upon completion of the project, LYMPHIT will boost the growth of our company generating additional 64 FTEs, revenues of €398M and a ROI of 10.25 by the fifth year after Phase 2 execution. With the help of the SME instrument, Dicronis aims to complete the product optimization and clinical validation so that it can be commercialized across European markets first, and global markets later on, improving the quality of care of healthcare systems worldwide as well as the lymphedema patient´s quality of life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LYMPHIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LYMPHIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

AMBRPAY (2019)

Decentralized subscription payments with cryptocurrency

Read More